These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 23143347)
1. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347 [TBL] [Abstract][Full Text] [Related]
2. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215 [TBL] [Abstract][Full Text] [Related]
3. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630 [TBL] [Abstract][Full Text] [Related]
5. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895 [TBL] [Abstract][Full Text] [Related]
6. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study. Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527 [TBL] [Abstract][Full Text] [Related]
7. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder. Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846 [TBL] [Abstract][Full Text] [Related]
8. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Preen DB; Calver J; Sanfilippo FM; Bulsara M; Holman CD Aust N Z J Public Health; 2007 Apr; 31(2):120-6. PubMed ID: 17461001 [TBL] [Abstract][Full Text] [Related]
9. An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. Raman SR; Marshall SW; Gaynes BN; Haynes K; Naftel AJ; Stürmer T Psychiatr Serv; 2015 Jun; 66(6):617-24. PubMed ID: 25726974 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Shin JY; Roughead EE; Park BJ; Pratt NL BMJ; 2016 May; 353():i2550. PubMed ID: 27245699 [TBL] [Abstract][Full Text] [Related]
11. Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder. Kariyawasam SH; Zaw F; Handley SL Neuro Endocrinol Lett; 2002 Feb; 23(1):45-8. PubMed ID: 11880861 [TBL] [Abstract][Full Text] [Related]
12. Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. Faber A; Kalverdijk LJ; de Jong-van den Berg LT; Hugtenburg JG; Minderaa RB; Tobi H J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):432-40. PubMed ID: 16958568 [TBL] [Abstract][Full Text] [Related]
13. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Kempton S; Vance A; Maruff P; Luk E; Costin J; Pantelis C Psychol Med; 1999 May; 29(3):527-38. PubMed ID: 10405075 [TBL] [Abstract][Full Text] [Related]
14. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137 [TBL] [Abstract][Full Text] [Related]
15. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Barner JC; Khoza S; Oladapo A Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228 [TBL] [Abstract][Full Text] [Related]
16. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS Value Health; 2008; 11(3):376-88. PubMed ID: 18489664 [TBL] [Abstract][Full Text] [Related]
17. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use? Calver J; Sanfilippo F; Preen D; Bulsara M Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573 [TBL] [Abstract][Full Text] [Related]
18. Medium-term outcomes are comparable with short-term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Efron D; Jarman FC; Barker MJ J Paediatr Child Health; 2000 Oct; 36(5):457-61. PubMed ID: 11036801 [TBL] [Abstract][Full Text] [Related]
19. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Dalsgaard S; Leckman JF; Mortensen PB; Nielsen HS; Simonsen M Lancet Psychiatry; 2015 Aug; 2(8):702-709. PubMed ID: 26249301 [TBL] [Abstract][Full Text] [Related]
20. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ; Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]